The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Managing frail patients with myeloma: assessing frailty and personalizing treatment
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, provides insight into the complexities of treating frail patients with multiple myeloma (MM), noting that frailty is a multifactorial concept involving comorbidities, psychological and cognitive factors, as well as social environment. Prof. Mohty emphasizes that carefully assessing frailty is essential, as treatment approaches should balance efficacy with potential toxicity, and highlights that frailty is a dynamic parameter that can change over time. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
